This medication was pulled due to the risk of heart valve problems and increased blood pressure in the lungs caused by fenfluramine, which can be deadly (10)
However, it is difficult to ascertain whether this was due to specific biology or the lack of statistical power after adjustment for multiplicity in STEP 2 due to a smaller sample size
Our goal at Rivas Medical Weight Loss is to provide our patients with the tools and information to achieve a reduced weight and maintain the loss long term

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself

You might see it mentioned online but please be careful